Stocktoria

Inhibikase Therapeutics, Inc. IKT

Nasdaq · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2020-12-23 · LEI

Inhibikase Therapeutics, Inc. statistics & valuation

Market cap$252.2M
P / B1.5×
Return on equity-27.9%
Return on capital-30.1%

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Gross margin (%)
202020212022202320242025
Operating margin (%)
-403.50% -476.20% -14686.20% -7712.00% 202020212022202320242025
Return on equity (%)
-29.10% -38.50% -85.80% -173.30% -29.00% -27.90% 202020212022202320242025
Shares outstanding
10.1M 25.2M 4.2M 6.2M 69.4M 131.7M 202020212022202320242025
Net debt ($)
-$40.5M -$8.8M 202020212022202320242025
Share buybacks ($)
202020212022202320242025
Return on assets (%)
-19.30% -34.80% -72.40% -131.20% -27.90% -26.60% 202020212022202320242025
Free cash flow margin (%)
-461.10% -14253.40% -6947.90% 202020212022202320242025
Debt / equity (×)
0.01× 0.03× 202020212022202320242025
EPS ($)
-$0.81 -$4.28 -$3.16 -$1.16 -$0.49 202020212022202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023FY2022FY2021FY2020
Operating margin——-7712.0%-14686.2%-476.2%-403.5%
Net margin——-7304.7%-14625.9%-476.9%-407.7%
FCF margin——-6947.9%-14253.4%-461.1%—
Return on assets-26.6%-27.9%-131.2%-72.4%-34.8%-19.3%
Return on equity-27.9%-29.0%-173.3%-85.8%-38.5%-29.1%
Debt / equity——0.03×—0.01×—
Current ratio21.7026.374.136.5910.473.13

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.